Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11604758 | 0.91 | MAPT (0.57) | MAPTKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL11796342 | 0.89 | PNLIP (0.55) | MAPTKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL9429444 | 0.87 | MAPT (0.51) | MAPTKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL19126084 | 0.86 | ALDH1A1 (0.53) | MAPTKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL5605061 | 0.84 | MAPT (0.51) | MAPTKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL9238262 | 0.83 | MAPT (0.50) | MAPTKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL23370784 | 0.81 | MAPT (0.55) | MAPTKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL21248415 | 0.81 | MAPT (0.55) | MAPTKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL6334182 | 0.80 | ALK (0.50) | MAPTKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL6333882 | 0.80 | ALK (0.50) | MAPTKMT2AL3MBTL1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377536-A4 | SELF-REDUCING ANTHRAQUINONE COMPOUNDS | COMMW SCIENT AND RES ORGANISAT (AU) | 2007-02-28 | — | — | EP | claimed |
| US-20040175314-A1 | Self-reducing anthraquinone compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORAGNISATION (AU) | 2004-09-09 | — | — | US | claimed |
| EP-1377536-A1 | SELF-REDUCING ANTHRAQUINONE COMPOUNDS | Commonwealth Scientific and Research Organisation (AU) | 2004-01-07 | — | — | EP | claimed |
| WO-2002076916-A1 | SELF-REDUCING ANTHRAQUINONE COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-10-03 | — | — | WO | claimed |
| EP-1377536-A4 | SELF-REDUCING ANTHRAQUINONE COMPOUNDS | COMMW SCIENT AND RES ORGANISAT (AU) | 2007-02-28 | — | — | EP | disclosed |
| US-20040175314-A1 | Self-reducing anthraquinone compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORAGNISATION (AU) | 2004-09-09 | — | — | US | disclosed |
| EP-1377536-A1 | SELF-REDUCING ANTHRAQUINONE COMPOUNDS | Commonwealth Scientific and Research Organisation (AU) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002076916-A1 | SELF-REDUCING ANTHRAQUINONE COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040175314-A1 | Self-reducing anthraquinone compounds | XDH, SQOR, NQO1 | MAPT 4666/4885KMT2A 2558/4885L3MBTL1 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.